ABSTRACT
A review of 377 rectal biopsies received in the Department of Pathology, Jinnah Postgraduate Medical Centre, Karachi, during the period 1963-1969 is presented. The significant findings were non-specific colitis in 37.93 percent of the cases, amoebic colitis in 8.75 percent cases and Juvenile polyps in 9.81 percent of the cases. No adenomatous polyp was seen in the series
Subject(s)
Humans , Male , Female , Biopsy , Rectal Neoplasms/diagnosis , Rectal Diseases/diagnosisABSTRACT
A study of the immunogenicity and safety of 20m recombinant DNA yeast derived hepatitis B vaccine was conducted in 153 Pakistani adults. All participants were in good physical condition had negative hepatitis B serological markers [HbsAg, anti HBs, anti-HBc] and normal ALT. Anti-HBs developed in 33 percent, 81 percent and 98 percent of subjects one month after the first, second and third dose respectively. Minor systemind local side-effects were observed in 30 percent of individuals. We conclude that yeast derived hepatitis B vaccine is safe, effective and immunogenic in Pakistani adults
Subject(s)
Humans , Male , Female , Hepatitis B Antibodies , Hepatitis B Surface Antigens , Hepatitis B Vaccines/biosynthesis , Saccharomyces cerevisiaeABSTRACT
Albendazole and metronidazole were compared in 68 patients diagnosed positive for giardiasis. Albendazole 1200 mg, one dose was given to 24 patients, albendazole 400 mg twice a day for 3 days was given to 23 patients, and metronidazole 400 mg 3 times a day for 5 days to 21 patients. Response to therapy was monitored by clinical examination and analysis of fresh faecal samples on days 0, 3, 7 and 10. Response to the single dose of albendazole was 55%, to the divided dose of albendazole 70%, and to metronidazole 84%. The results show that albendazole, originally recommended for helminthic infection, can also be used in patients with mixed protozoal infection or for infections resistant to metronidazole
Subject(s)
Adolescent , Adult , Aged , Female , Humans , Male , Middle Aged , Antiprotozoal Agents , Drug Resistance , Feces/parasitology , Giardiasis/drug therapy , MetronidazoleABSTRACT
A study was conducted to test the response to therapy and the relapse rates of endoscopically-confirmed duodenal ulcers. Endoscopy to check for healing was performed at 4 and 8 weeks in cases receiving H2-blockers and misoprostol and at 14 and 28 days in cases receiving a proton pump inhibitor. Endoscopy was repeated at 1, 3, 6 and 12 months to check for relapses. Healing rates were 61%-77% and 75%-85% at 4 and 8 weeks in the group receiving H2-blockers and misoprostol. Healing rates were 68% and 100% at days 14 and 28 with the proton pump inhibitor. The relapse rates within 3 months were 72%-86% and 100% respectively. This study indicates that the faster the ulcer healed, the earlier the relapse occurred
Subject(s)
Female , Humans , Male , Wound Healing , Treatment Outcome , Follow-Up Studies , Remission Induction , Recurrence , Endoscopy, Digestive System , Proton Pump Inhibitors , Anti-Ulcer Agents , Histamine H2 Antagonists , MisoprostolABSTRACT
Thirty nine Helicobacter pylori [HP] positive chronic duodenal ulcer patients completed the 4 weeks treatment of triple therapy [Denol, Metronidazole and Amoxil]. Of these 29 showed healed duodenal ulcer and negative CLO test at 8 weeks [eradication]. They were followed at 3.6 and 12 months and at each follow-up, endoscopy and CLO testing were repeated. At 12 weeks, 54% showed a healed ulcer and negative CLO and these figures reached to 69 and 66% at 6 and 12 months respectively. Thirty percent relapsed within 1 year. The present study indicates a prolonged remission of duodenal ulcer following HP eradication